Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jennifer Diamond to Doxorubicin

This is a "connection" page, showing publications Jennifer Diamond has written about Doxorubicin.

 
Connection Strength
 
 
 
0.253
 
  1. Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JR. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer. Oncology (Williston Park). 2018 06; 32(6):298-302.
    View in: PubMed
    Score: 0.132
  2. Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park). 2009 Aug; 23(9):784-91.
    View in: PubMed
    Score: 0.072
  3. Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez ATA, Dus ED, Binns CA, MacBeth M, Whitty PA, Diamond JR, Pitts TM. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis. Breast Cancer Res. 2024 03 01; 26(1):35.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)